Fullerenes for cancer diagnosis and therapy: Preparation, biological and clinical perspectives

Current Drug Metabolism

Volumn 13, Issue 8, 2012, Pages 1035-1045

  Chen, Zhiyun ^a   Mao, Ruoqing ^a   Liu, Ying ^a  

^a NATIONAL CENTER FOR NANOSCIENCE AND TECHNOLOGY   (China)

Author keywords

Biological applications; Cancer treatment; Fullerene; Nanomaterials

Indexed keywords

ANTINEOPLASTIC AGENT; BUCKY AMINO ACID; CARBOXYFULLERENE; CYSTINE C 60 DERIVATIVE; DENDROFULLERENE; DOXORUBICIN; DRUG CARRIER; E,E,E TRIS MALONIC ACID FULLERENE DERIVATIVE; ERYTHROPOIETIN; FOLIC ACID; FULLERENE; FULLERENE DERIVATIVE; FULLERENOL; GADOLINIUM; GADOLINIUM ENDOHEDRAL METALLOFULLERENOL; GLUTATHIONE TRANSFERASE; LUTETIUM; NANOPARTICLE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; PACLITAXEL; PHOTOSENSITIZING AGENT; PLASMID DNA; POLY N,N DIMETHYLFULLEROPYRROLIDINIUM DERIVATIVE; POLYHYDROXYLATED ENDOHEDRAL METALLOFULLERENE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; SUPEROXIDE DISMUTASE; TETRAAMINOFULLERENE; TETRAPIPERIDINOFULLERENE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANEMIA; ANTIANGIOGENIC ACTIVITY; ANTIOXIDANT ACTIVITY; AUTOPHAGY; BONE TUMOR; BREAST CANCER; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER THERAPY; CELL SPECIFICITY; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG SOLUBILITY; DRUG SYNTHESIS; GENE VECTOR; GENETIC TRANSFECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOMODULATION; LEWIS CARCINOMA; LIPID PEROXIDATION; LIVER CELL CARCINOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PHOTODYNAMIC THERAPY; POSITRON EMISSION TOMOGRAPHY; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOOT; TH1 CELL; VAPORIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; FULLERENES; HUMANS; NEOPLASMS;

EID: 84868032139     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920012802850128     Document Type: Review

References (107)

1. Jemal, A.; Siegel, R.; Xu, J.; Ward, E. Cancer statistics, 2010. CA Cancer J. Clin., 2010, 60(5), 277-300.
2. Peer, D.; Karp, J.M.; Hong, S.; Farokhzad, O.C.; Margalit, R.; Langer, R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol., 2007, 2(12), 751-760.
3. Wang, X.; Yang, L.; Chen, Z.G.; Shin, D.M. Application of nanotechnology in cancer therapy and imaging. CA Cancer J. Clin., 2008, 58(2), 97-110.
4. Kroto, H.W.; Heath, J.R.; O'Brien, S.C.; Curl, R.F.; Smalley, R.E. C60: Buckminsterfullerene. Nature, 1985, 318(6042), 162-163.
5. Fowler, P.W.; Ceulemans, A. Electron deficiency of the fullerenes. J. Phys. Chem. A, 1995, 99(2), 508-510.
6. Krätschmer, W.; Lamb, L.D.; Fostiropoulos, K.; Huffman, D.R. Solid C60: a new form of carbon. Nature, 1990, 347(27), 354-358.
7. Chiang, L.Y.; Upasani, R.B.; Swirczewski, J.W. Versatile nitronium chemistry for C60 fullerene functionalization. J. Am. Chem. Soc., 1992, 114(26), 10154-10157.
8. Naim, A.; Shevlin, P.B. Reversible addition of hydroxide to the fullerenes. Tetrahedron Lett., 1992, 33(47), 7097-7100.
9. Chiang, L.Y.; Upasani, R.B.; Swirczewski, J.W.; Soled, S. Evidence of hemiketals incorporated in the structure of fullerols derived from aqueous acid chemistry. J. Am. Chem. Soc., 1993, 115(13), 5453-5457.
10. Li, J.; Takeuchi, A.; Ozawa, M.; Li, X.; Saigo, K.; Kitazawa, K. C60 fullerol formation catalysed by quaternary ammonium hydroxides. J. Chem. Soc. Chem. Commun., 1993, 1784-1785.
11. Lamparth, I.; Hirsch, A. Water-soluble malonic acid derivatives of C60 with a defined three-dimensional structure. J. Chem. Soc. Chem. Commun., 1994, 1727-1728.
12. Brettreich, M.; Hirsch, A. A highly water-soluble dendro[60]fullerene. Tetrahedron Lett., 1998, 39(18), 2731-2734.
13. Hu, Z.; Guan, W.C.; Wang, W.; Huang, L.Z.; Xing, H.P.; Zhu, Z. Protective effect of a novel cystine C60 derivative on hydrogen peroxide-induced apoptosis in rat pheochromocytoma PC12 cells. Chem. Biol. Interact., 2007, 167(2), 135-144.
14. Hu, Z.; Guan, W.C.; Wang, W.; Zhu, Z.; Wang, Y. Folacin C60 derivative exerts a protective activity against oxidative stress-induced apoptosis in rat pheochromocytoma cells. Bioorg. Med. Chem. Lett., 2010, 20(14), 4159-4162.
15. Hu, Z.; Guan, W.C.; Wang, W.; Huang, L.Z.; Xing, H P.; Zhu, Z. Synthesis of [beta]-alanine C60 derivative and its protective effect on hydrogen peroxide-induced apoptosis in rat pheochromocytoma cells. Cell Biol. Int., 2007, 31(8), 798-804.
16. Hu, Z.; Guan, W.C.; Wang, W.; Huang, L.Z.; Tang, X.Y.; Xu, H.; Zhu, Z.; Xie, X.Z.; Xing, H.P. Synthesis of amphiphilic amino acid C60 derivatives and their protective effect on hydrogen peroxide-induced apoptosis in rat pheochromocytoma cells. Carbon, 2008, 46 (1), 99-109.
17. Heath, J.R.; O'Brien, S.C.; Zhang, Q.; Liu, Y.; Curl, R.F.; Kroto, H.W.; Tittel, F.K.; Smalley, R.E. Lanthanum complexes of spheroidal carbon shells. J. Am. Chem. Soc., 1985, 107 (25), 7779-7780.
18. Chai, Y.; Guo, T.; Jin, C.; Haufler, R.E.; Chibante, L.P.F.; Fure, J.; Wang, L.; Alford, J.M.; Smalley, R.E. ChemInform Abstract: Fullerenes with Metals Inside. ChemInform, 1991, 22(52).
19. Shinohara, H. Endohedral metallofullerenes. Rep. Prog. Phys., 2000, 63(6), 843.
20. Chen, C.Y.; Xing, G.M.; Wang, J.X.; Zhao, Y.L.; Li, B.; Tang, J.; Jia, G.; Wang, T.C.; Sun, J.; Xing, L.; Yuan, H.; Gao, Y.X.; Meng, H.; Chen, Z.; Zhao, F.; Chai, Z.F.; Fang, X.H. Multihydroxylated [GdC82(OH)22]n nanoparticles: antineoplastic activity of high efficiency and low toxicity. Nano. Lett., 2005, 5(10), 2050-2057.
21. Iagaru, A.; Masamed, R.; Keesara, S.; Conti, P.S. Breast MRI and 18F FDG PET/CT in the management of breast cancer. Ann. Nucl. Med., 2007, 21(1), 33-38.
22. Atri, M. New technologies and directed agents for applications of cancer imaging. J. Clin. Oncol., 2006, 24(20), 3299-3308.
23. Gambhir, S.S. Molecular imaging of cancer with positron emission tomography. Nat. Rev. Cancer, 2002, 2(9), 683-693.
24. Mody, V.V.; Nounou, M.I.; Bikram, M. Novel nanomedicine-based MRI contrast agents for gynecological malignancies. Adv. Drug Deliv. Rev., 2009, 61(10), 795-807.
25. Gao, Y.X.; Chen C.Y.; Chai, Z.F. Advanced nuclear analytical techniques for metalloproteomics. J. Anal. At. Spectrom., 2007, 22, 856-866.
26. Zhang, J.; Fatouros, P.P.; Shu, C.; Reid, J.; Owens, L.S.; Cai, T.; Gibson, H.W.; Long, G.L.; Corwin, F.D.; Chen, Z.J.; Dorn, H.C. High relaxivity trimetallic nitride (Gd3N) metallofullerene MRI contrast agents with optimized functionality. Bioconjug. Chem., 2010, 21(4), 610-615.
27. Shu, C.; Corwin, F.D.; Zhang, J.; Chen, Z.; Reid, J.E.; Sun, M.; Xu, W.; Sim, J.H.; Wang, C.; Fatouros, P.P.; Esker, A.R.; Gibson, H.W.; Dorn, H.C. Facile preparation of a new gadofullerene-based magnetic resonance imaging contrast agent with high 1H relaxivity. Bioconjug. Chem., 2009, 20(6), 1186-1193.
28. Braun, K.; Dunsch, L.; Pipkorn, R.; Bock, M.; Baeuerle, T.; Yang, S.; Waldeck, W.; Wiessler, M. Gain of a 500-fold sensitivity on an intravital MR contrast agent based on an endohedral gadolinium cluster fullerene conjugate: a new chance in cancer diagnostics. Int. J. Med. Sci., 2010, 7(3), 136-146.
29. Qingnuan, L.; yan, X.; Xiaodong, Z.; Ruili, L.; qieqie, D.; Xiaoguang, S.; Shaoliang, C.; Wenxin, L. Preparation of (99m)Tc-C(60)(OH)(x) and its biodistribution studies. Nucl. Med. Biol., 2002, 29(6), 707-710.
30. Wang, J.X.; Chen, C.Y.; Li, B.; Yu, H.; Zhao, Y.L.; Sun, J.; Li, Y.F.; Xing, G.M.; Yuan, H.; Tang, J.; Chen, Z.; Meng, H.; Gao, Y.X.; Ye, C.; Chai, Z.F.; Zhu, C.; Ma, B.; Fang, X.F.; Wan, L. Antioxidative function and biodistribution of [GdC82(OH)22]n nanoparticles in tumor-bearing mice. Biochem. Pharmacol., 2006, 71(6), 872-881.
31. Zakharian, T.Y.; Seryshev, B.; Sitharaman, A.; Gilbert, B.E.; Knight, V.; Wilson, L.J. A fullerene-paclitaxel chemotherapeutic: synthesis, characterization, and study of biological activity in tissue culture. J. Am. Chem. Soc., 2005, 127(36), 12508-12509.
32. Partha, R.; Mitchell, L.R.; Lyon, J.L.; Joshi, P.P.; Conyers, J.L. Buckysomes: fullerene-based nanocarriers for hydrophobic molecule delivery, ACS Nano, 2008, 2(9), 1950-1958.
33. Bogdanovic, G.; Kojic, V.; Dordevic, A.; Canadanovic-Brunet, J.; Vojinovic-Miloradov, M.; Baltic, V.V. Modulating activity of fullerol C60(OH)22 on doxorubicin-induced cytotoxicity. Toxicol. In Vitro, 2004, 18(5), 629-637.
34. Injac, R.; Perse, M.; Obermajer, N.; Djordjevic-Milic, V.; Prijatelj, M.; Djordjevic, A.; Cerar, A.; Strukelj, B. Potential hepatoprotective effects of fullerenol C60(OH)24 in doxorubicin-induced hepatotoxicity in rats with mammary carcinomas. Biomaterials, 2008, 29(24-25), 3451-3460.
35. Injac, R.; Perse, M.; Cerne, M.; Potocnik, N.; Radic, N.; Govedarica, B.; Djordjevic, A.; Cerar, A.; Strukelj, B. Protective effects of fullerenol C60(OH)24 against doxorubicin-induced cardiotoxicity and hepatotoxicity in rats with colorectal cancer. Biomaterials, 2009, 30(6), 1184-1196.
36. Lu, F.; Haque, S.A.; Yang, S.T.; Luo, P.G.; Gu, L.; Kitaygorodskiy, A.; Li, H.; Lacher, S.; Sun, Y.P. Aqueous Compatible Fullerene-Doxorubicin Conjugates. J. Phys. Chem. C., 2009, 113(41), 17768-17773.
37. Chaudhuri, P.; Paraskar, A.; Soni, S.; Mashelkar, R.A.; Sengupta, S. Fullerenol-cytotoxic conjugates for cancer chemotherapy. ACS Nano, 2009, 3(9), 2505-2514.
38. Liu, J.H.; Cao, L.; Luo, P.G.; Yang, S.T.; Lu, F.; Wang, H.; Meziani, M.J.; Haque, S.A.; Liu, Y.; Lacher, S.; Sun, Y.P. Fullerene-conjugated doxorubicin in cells. ACS Appl. Mater. Interfaces, 2010, 2(5), 1384-1389.
39. Venkatesan, N.; Yoshimitsu, J.; Ito, Y.; Shibata, N.; Takada, K. Liquid filled nanoparticles as a drug delivery tool for protein therapeutics. Biomaterials, 2005, 26(34), 7154-7163.
40. Sitharaman, B.; Zakharian, T.Y.; Saraf, A.; Misra, P.; Ashcroft, J.; Pan, S.; Pham, Q.P.; Mikos, A.G.; Wilson, L.J.; Engler, D.A. Water-soluble fullerene (C60) derivatives as nonviral gene-delivery vectors. Mol. Pharm., 2008, 5(4), 567-578.
41. Isobe, H.; Nakanishi, W.; Tomita, N.; Jinno, S.; Okayama, H.; Nakamura, E. Nonviral gene delivery by tetraamino fullerene. Mol. Pharm., 2006, 3(2), 124-134.
42. Isobe, H.; Nakanishi, W.; Tomita, N.; Jinno, S.; Okayama, H.; Nakamura, E. Gene delivery by aminofullerenes: structural requirements for efficient transfection. Chem. Asian J., 2006, 1(1-2), 167-175.
43. Ying, Q.; Zhang, J.; Liang, D.; Nakanishi, W.; Isobe, H.; Nakamura, E.; Chu, B. Fractal behavior of functionalized fullerene aggregates. I. Aggregation of two-handed tetraaminofullerene with DNA. Langmuir, 2005, 21(22), 9824-9831.
44. Burger, C.; Chu, B. Functional nanofibrous scaffolds for bone reconstruction. Colloid. Surface. B., 2007, 56(1-2), 134-141.
45. Klumpp, C.; Lacerda, L.; Chaloin, O.; Da Ros, T.; Kostarelos, K.; Prato, M.; Bianco, A. Multifunctionalised cationic fullerene adducts for gene transfer: design, synthesis and DNA complexation. Chem. Commun., 2007, 28(36), 3762-3764.
46. Yang, J.; Alemany, L.B.; Driver, J.; Hartgerink, J.D.; Barron, A.R. Fullerene-derivatized amino acids: synthesis, characterization, antioxidant properties, and solid-phase peptide synthesis. Chem. Eur. J., 2007, 13(9), 2530-2545.
47. Zhang, L.W.; Yang, J.; Barron, A.R.; Monteiro-Riviere, N.A. Endocytic mechanisms and toxicity of a functionalized fullerene in human cells. Toxicol. Lett., 2009, 191(2-3), 149-157.
48. Dolmans, D.E.; Fukumura, D.; Jain, R.K. Photodynamic therapy for cancer. Nat. Rev. Cancer, 2003, 3(5), 380-387.
49. Renno, R.Z.; Terada, Y.; Haddadin, M.J.; Michaud, N.A.; Gragoudas, E.S.; Miller, J.W. Selective photodynamic therapy by targeted verteporfin delivery to experimental choroidal neovascularization mediated by a homing peptide to vascular endothelial growth factor receptor-2. Arch. Ophthalmol., 2004, 122(7), 1002-1011.
50. Lu, F.; Hu, Z.; Sinard, J.; Garen, A.; Adelman, R. A. Factor VII-verteporfin for targeted photodynamic therapy in a rat model of choroidal neovascularization. Invest. Ophthalmol. Vis. Sci., 2009, 50(8), 3890-3896.
51. Tabata, Y.; Murakami, Y.; Ikada, Y. Photodynamic effect of polyethylene glycol-modified fullerene on tumor. Jpn. J. Cancer Res., 1997, 88, 1108-1116.
52. Liu, J.; Ohta, S.; Sonoda, A.; Yamada, M.; Yamamoto, M.; Nitta, N.; Murata, K.; Tabata, Y. Preparation of PEG-conjugated fullerene containing Gd3+ ions for photodynamic therapy. J. Control. Release, 2007, 117(1), 104-110.
53. Liu, J.; Tabata, Y. Photodynamic Antitumor Activity of Fullerene Modified with Poly(ethylene glycol) with Different Molecular Weights and Terminal Structures. J. Biomater. Sci. Polym. Ed. 2011, 22(1-3), 297-312.
54. Liu, J.; Tabata, Y. Photodynamic therapy of fullerene modified with pullulan on hepatoma cells. J. Drug Target, 2010, 18(8), 602-610.
55. Jiang, G.C.; Li, G.T. Synthesis, characterization and biological activity of C60 derivative. J. Appl. Polym. Sci., 2007, 104(5), 3120-3123.
56. Prylutska, S.V.; Grynyuk, II; Palyvoda, K.O.; Matyshevska, O.P. Photoinduced cytotoxic effect of fullerenes C60 on transformed T-lymphocytes. Exp. Oncol., 2010, 32(1), 29-32.
57. Otake, E.; Sakuma, S.; Torii, K.; Maeda, A.; Ohi, H.; Yano, S.; Morita, A. Effect and Mechanism of a New Photodynamic Therapy with Glycoconjugated Fullerene. Photochem. Photobiol., 2010, 86(6), 1356-1363.
58. Roberts, J.E.; Wielgus, A.R.; Boyes, W.K.; Andley, U.; Chignell, C.F. Phototoxicity and cytotoxicity of fullerol in human lens epithelial cells. Toxicol. Appl. Pharmacol., 2008, 228(1), 49-58.
59. Zhao, B.; He, Y.Y.; Chignell, C.F.; Yin, J.J.; Andley, U.; Roberts, J.E. Difference in phototoxicity of cyclodextrin complexed fullerene[(gamma-CyD)2/ C60] and its aggregated derivatives toward human lens epithelial cells. Chem. Res. Toxicol., 2009, 22(4), 660-667.
60. Mroz, P.; Pawlak, A.; Satti, M.; Lee, H.; Wharton, T.; Gali, H.; Sarna, T.; Hamblin, M.R. Functionalized fullerenes mediate photodynamic killing of cancer cells: Type I versus Type II photochemical mechanism. Free Radical Bio. Med., 2007, 43(5), 711-719.
61. Wielgus, A.R.; Zhao, B.; Chignell, C.F.; Hu, D.N.; Roberts, J.E. Phototoxicity and cytotoxicity of fullerol in human retinal pigment epithelial cells. Toxicol. Appl. Pharmacol., 2010, 242(1), 79-90.
62. Constantin, C.; Neagu, M.; Ion, R.M.; Gherghiceanu, M.; Stavaru, C. Fullerene-porphyrin nanostructures in photodynamic therapy. Nanomedicine, 2010, 5(2), 307-317.
63. Meng, H.; Xing, G.M.; Sun, B.Y.; Zhao, F.; Lei, H.; Li, W.; Song, Y.; Chen, Z.; Yuan, H.; Wang, X.; Long, J.; Chen, C.Y.; Liang, X.J.; Zhang, N., Chai, Z.F.; Zhao, Y.L. Potent angiogenesis inhibition by the particulate form of fullerene derivatives. ACS Nano., 2010, 4(5), 2773-2783.
64. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med., 1971, 285(21), 1182-1186.
65. Wang, R.; Chadalavada, K.; Wilshire, J.; Kowalik, U.; Hovinga, K.E.; Geber, A.; Fligelman, B.; Leversha, M.; Brennan, C.; Tabar, V. Glioblastoma stem-like cells give rise to tumour endothelium. Nature, 2010, 428(7325), 829-833.
66. Ricci-Vitiani, L.; Pallini, R.; Biffoni, M.; Todaro, M.; Invernici, G.; Cenci, T.; Maira, G.; Parati, E.A.; Stassi, G.; Larocca, L.M.; De Maria, R. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature, 2010, 468(7325), 824-828.
67. Kou, B.; Li, Y.; Zhang, L.; Zhu, G.; Wang, X.; Xia, J.; Shi, Y. In vivo inhibition of tumor angiogenesis by a soluble VEGFR-2 fragment. Exp. Mol. Pathol., 2004, 76(2), 129-137.
68. Jiao, F.; Liu, Y.; Qu, Y.; Li, W.; Zhou, G.Q.; Sun, B.Y.; Li, Y.F.; Zhao, Y.L.; Chen, C.Y. Studies on antitumor and antimetastatic activities of fullerenol in a mouse breast cancer model. Carbon, 2010, 48(8), 2231-2243.
69. Dobrovolskaia, M.A.; Aggarwal, P.; Hall, J.B.; McNeil, S.E. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol. Pharm., 2008, 5(4), 487-495.
70. Liu, Y.; Jiao, F.; Qiu, Y.; Li, W.; Qu, Y.; Tian, C.X.; Li, Y.; Bai, R.; Lao, F.; Zhao, Y.L.; Chai, Z.F.; Chen, C.Y. Immunostimulatory properties and enhanced TNF-alpha mediated cellular immunity for tumor therapy by C60(OH)20 nanoparticles. Nanotechnology, 2009, 20(41), 415102.
71. Liu, Y.; Jiao, F.; Qiu, Y.; Li, W.; Lao, F.; Zhou, G.Q.; Sun, B.Y.; Xing, G.M.; Dong, J.Q.; Zhao, Y.L.; Chai, Z.F.; Chen, C.Y. The effect of Gd@C82(OH)22 nanoparticles on the release of Th1/Th2 cytokines and induction of TNF-alpha mediated cellular immunity. Biomaterials, 2009, 30(23-24), 3934-3945.
72. Yang, D.; Zhao, Y.L.; Guo, H.; Li, Y.; Tewary, P.; Xing, G.M.; Hou, W.; Oppenheim, J.J.; Zhang, N. [Gd@C82(OH)22]n Nanoparticles Induce Dendritic Cell Maturation and Activate Th1 Immune Responses. ACS Nano., 2010, 4(2), 1178-1186.
73. Zhu, J.; Ji, Z.; Wang, J.; Sun, R.; Zhang, X.; Gao, Y.; Sun, H.; Liu, Y.; Wang, Z.; Li, A.; Ma, J.; Wang, T.; Jia, G.; Gu, Y. Tumorinhibitory effect and immunomodulatory activity of fullerol C60(OH)x. Small, 2008, 4(8), 1168-1175.
74. Zogovic, N.S.; Nikolic, N.S.; Vranjes-Djuric, S.D.; Harhaji, L.M.; Vucicevic, L.M.; Janjetovic, K.D.; Misirkic, M.S.; Todorovic-Markovic, B.M.; Markovic, Z.M.; Milonjic, S.K.; Trajkovic, V.S. Opposite effects of nanocrystalline fullerene (C(60)) on tumour cell growth in vitro and in vivo and a possible role of immunosupression in the cancer-promoting activity of C(60). Biomaterials, 2009, 30(36), 6940-6946.
75. Droge, W. Free radicals in the physiological control of cell function. Physiol. Rev., 2002, 82(1), 47-95.
76. Yin, J.J.; Lao, F.; Fu, P.P.; Wamer, W.G.; Zhao, Y.L.; Wang, P.C.; Qiu, Y.; Sun, B.Y.; Xing, G.M.; Dong, J.Q.; Liang, X.J.; Chen, C.Y. The scavenging of reactive oxygen species and the potential for cell protection by functionalized fullerene materials. Biomaterials, 2009, 30(4), 611-621.
77. Injac, R.; Boskovic, M.; Perse, M.; Koprivec-Furlan, E.; Cerar, A.; Djordjevic, A.; Strukelj, B. Acute doxorubicin nephrotoxicity in rats with malignant neoplasm can be successfully treated with fullerenol C60(OH)24 via suppression of oxidative stress. Pharmacol. Rep., 2008, 60(5), 742-749.
78. Injac, R.; Radic, N.; Govedarica, B.; Perse, M.; Cerar, A.; Djordjevic, A.; Strukelj, B. Acute doxorubicin pulmotoxicity in rats with malignant neoplasm is effectively treated with fullerenol C60(OH)24 through inhibition of oxidative stress. Pharmacol. Rep., 2009, 61(2), 335-342.
79. Hu, Z.; Guan, W.; Wang, W.; Zhu, Z.; Wang, Y. Folacin C60 derivative exerts a protective activity against oxidative stress-induced apoptosis in rat pheochromocytoma cells. Bioorg. Med. Chem. Lett., 2010, 20(14), 4159-4162.
80. Levine, B.; Kroemer, G. Autophagy in the pathogenesis of disease. Cell, 2008, 132(1), 27-42.
81. Johnson-Lyles, D.N.; Peifley, K.; Lockett, S.; Neun, B.W.; Hansen, M.; Clogston, J.; Stern, S.T.; McNeil, S.E. Fullerenol cytotoxicity in kidney cells is associated with cytoskeleton disruption, autophagic vacuole accumulation, and mitochondrial dysfunction. Toxicol. Appl. Pharmacol., 2010, 248(3), 249-258.
82. Zhang, Q.; Yang, W.; Man, N.; Zheng, F.; Shen, Y.; Sun, K.; Li, Y.; Wen, L.P. Autophagy-mediated chemosensitization in cancer cells by fullerene C60 nanocrystal. Autophagy, 2009, 5(8), 1107-1117.
83. Wei, P.; Zhang, L.; Lu, Y.; Man, N.; Wen, L. C60(Nd) nanoparticles enhance chemotherapeutic susceptibility of cancer cells by modulation of autophagy. Nanotechnology, 2010, 21(49), 495101.
84. Gottesman, M.M. Mechanisms of cancer drug resistance. Annu. Rev. Med., 2002, 53, 615-627.
85. Wang, D.; Lippard, S.J. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov., 2005, 4(4), 307-320.
86. McNeill, D.R.; Wilson, D.M., 3rd. A dominant-negative form of the major human abasic endonuclease enhances cellular sensitivity to laboratory and clinical DNA-damaging agents. Mol. Cancer Res., 2007, 5(1), 61-70.
87. Liang, X.J.; Meng, H.; Wang, Y.Z.; He, H.Y.; Meng, J.; Lu, J.; Wang, P.C.; Zhao, Y.L.; Gao, X.Y.; Sun, B.Y.; Chen, C.Y.; Xing, G.M.; Shen, D.; Gottesman, M.M.; Wu, Y.; Yin, J.J.; Jia, L. Metallofullerene nanoparticles circumvent tumor resistance to cisplatin by reactivating endocytosis. Proc. Natl. Acad. Sci. USA, 2010, 107(16), 7449-7454.
88. Moussa, F.; Pressac, M.; Genin, E.; Roux, S.; Trivin, F.; Rassat, A.; Céolin, R.; Szwarc, H. Quantitative analysis of C60 fullerene in blood and tissues by high-performance liquid chromatography with photodiode-array and mass spectrometric detection. J. Chromatogr. B. Biomed. Sci. Appl., 1997, 696(1), 153-159.
89. Rajagopalan, P.; Wudl, F.; Schinazi, R.F.; Boudinot, F.D. Pharmacokinetics of a water-soluble fullerene in rats. Antimicrob. Agents. Chemother., 1996, 40(10), 2262-2265.
90. Qingnuan, L.; yan, X.; Xiaodong, Z.; Ruili, L.; qieqie, D.; Xiaoguang, S.; Shaoliang, C.; Wenxin, L. Preparation of (99m)Tc-C(60)(OH)(x) and its biodistribution studies. Nucl. Med. Biol, 2002, 29(6), 707-710.
91. Cagle, D.W.; Kennel, S.J.; Mirzadeh, S.; Alford, J.M.; Wilson, L.J. In vivo studies of fullerene-based materials using endohedral metallofullerene radiotracers. Proc. Natl. Acad. Sci. USA, 1999, 96(9), 5182-5187.
92. Diener, M.D.; Alford, J.M.; Kennel, S.J.; Mirzadeh, S. (212)PbC(60) and its water-soluble derivatives: synthesis, stability, and suitability for radioimmunotherapy. J. Am. Chem. Soc, 2007, 129(16), 5131-5138.
93. Mikawa, M.; Kato, H.; Okumura, M.; Narazaki, M.; Kanazawa, Y.; Miwa, N.; Shinohara, H. Paramagnetic water-soluble metallofullerenes having the highest relaxivity for MRI contrast agents. Bioconjug. Chem., 2001, 12(4), 510-514.
94. Mashino, T.; Shimotohno, K.; Ikegami, N.; Nishikawa, D.; Okuda, K.; Takahashi, K.; Nakamura, S.; Mochizuki, M. Human immunodeficiency virus-reverse transcriptase inhibition and hepatitis C virus RNA-dependent RNA polymerase inhibition activities of fullerene derivatives. Bioorg. Med. Chem. Lett., 2005, 15(4), 1107-1109.
95. Lao, F.; Chen, L.; Li, W.; Ge, C.; Qu, Y.; Sun, Q.; Zhao, Y.; Han, D.; Chen, C.Y. Fullerene nanoparticles selectively enter oxidation-damaged cerebral microvessel endothelial cells and inhibit jnk-related apoptosis. ACS Nano, 2009, 3(11), 3358-3368.
96. Lao, F.; Li, W.; Han, D.; Qu, Y.; Liu, Y.; Zhao, Y.L.; Chen, C.Y. Fullerene derivatives protect endothelial cells against NO-induced damage. Nanotechnology, 2009, 20(22), 225103.
97. Lyon, D.Y.; Adams, L.K.; Falkner, J.C.; Alvarezt, P.J. Antibacterial activity of fullerene water suspensions: effects of preparation method and particle size. Environ. Sci. Technol, 2006, 40(14), 4360-4366.
98. Lyon, D.Y.; Brunet, L.; Hinkal, G.W.; Wiesner, M.R.; Alvarez, P.J. Antibacterial activity of fullerene water suspensions (nC60) is not due to ROS-mediated damage. Nano. Lett., 2008, 8(5), 1539-1543.
99. Kumar, A.; Patel, G.; Menon, S.K. Fullerene isoniazid conjugate - a tuberculostat with increased lipophilicity: synthesis and evaluation of antimycobacterial activity. Chem. Biol. Drug Des., 2009, 73(5), 553-557.
100. Mashino, T.; Usui, N.; Okuda, K.; Hirota, T.; Mochizuki, M. Respiratory chain inhibition by fullerene derivatives: Hydrogen peroxide production caused by fullerene derivatives and a respiratory chain system. Bioorg. Med. Chem. Lett, 2003, 11(7), 1433-1438.
101. Tang, Y.J.; Ashcroft, J.M.; Chen, D.; Min, G.; Kim, C.H.; Murkhejee, B.; Larabell, C.; Keasling, J.D.; Chen, F.F. Charge-associated effects of fullerene derivatives on microbial structural integrity and central metabolism. Nano Lett, 2007, 7(3), 754-760.
102. Mashino, T.; Shimotohno, K.; Ikegami, N.; Nishikawa, D.; Okuda, K.; Takahashi, K.; Nakamura, S.; Mochizuki, M. Human immunodeficiency virus-reverse transcriptase inhibition and hepatitis C virus RNA-dependent RNA polymerase inhibition activities of fullerene derivatives. Bioorg. Med. Chem. Lett, 2005 15(4), 1107-1109.
103. Johansson, L.; Chen, C.Y.; Thorell, J.O.; Fredriksson, A.; Stone-Elander, S.; Gafvelin, G.; Arner, E.S.J. Exploiting the 21st amino acid-purifying and labeling proteins by selenolate targeting. Nat. Methods, 2004, 1 (1), 61-66.
104. Ibrahim, M.; Saleh, N.A.; Hameed, A.J.; Elshemey, W.M.; Elsayed, A.A. Structural and electronic properties of new fullerene derivatives and their possible application as HIV-1 protease inhibitors. Spectrochim. Acta. A, 2010, 75(2), 702-709.
105. Kato, S.; Taira, H.; Aoshima, H.; Saitoh, Y.; Miwa, N. Clinical evaluation of fullerene-C60 dissolved in squalane for anti-wrinkle cosmetics. J. Nanosci. Nanotechnol, 2010, 10(10), 6769-6774.
106. Chen, Z.; Meng, H; Xing, G.M.; Chen, C.Y., Zhao Y.L. Toxicological and biological effects of nanomaterials. Int. J. Nanotech., 2007, 4, 179-196.
107. Aoshima, H.; Saitoh, Y.; Ito, S.; Yamana, S.; Miwa, N. Safety evaluation of highly purified fullerenes (HPFs): based on screening of eye and skin damage. J. Toxicol. Sci., 2009, 34(5), 555-562.